SCHD’s Dividend Quality Filter Now Concentrates 42 Percent of Your Money in Just Ten Stocks

Most investors buy Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD | SCHD Price Prediction) because the fund’s reputation tells them they are buying diversification. SCHD has 105 holdings, screens hard on dividend quality, and charges 0.06%.

The retiree who built an income sleeve around SCHD usually has not read the holdings list. Read the list and the diversification story bends: the top ten positions sit at ~42% of the fund.

What SCHD does

The fund tracks the Dow Jones U.S. Dividend 100 Index, which screens U.S. companies on a ten-year dividend history, cash flow to total debt, return on equity, dividend yield, and five-year dividend growth. It reconstitutes every March and rebalances quarterly. SCHD is therefore a quality-tilted dividend basket built around mature businesses paying ordinary qualified dividends out of operating cash flow.

The screen does its job at the security level. Top holdings include** Texas Instruments** (NASDAQ:TXN), UnitedHealth (NYSE:UNH), and Qualcomm (NASDAQ:QCOM). Each name passes the quality filter. The aggregation is what the brochure does not advertise.

Does it deliver?

This year, yes. SCHD is up 21% year-to-date against 9% for the S&P 500, helped by energy doing real work. Crude went from $60 in January to ~$90 today, and Chevron (NYSE:CVX) rode that to a 47% one-year gain. Stretch the window and the picture inverts. Over five years SCHD has returned 53% in price against 92% for SPY.

The tradeoffs the fact sheet underplays

Three concentrations are worth pricing in before you treat SCHD as a diversifier.

• The pharma cluster. Many of SCHD’s pharma holdings are walking through patent cliffs. Humira biosimilars chewed AbbVie’s (NYSE:ABBV) Humira sales to $688 million last quarter, a 39% drop year over year. Revlimid loses U.S. exclusivity in November 2026. JANUVIA is already off 28% from generic pressure. The screen rewarded their dividend histories. It cannot see the patent calendar.

• Energy holdings move with the same barrel of oil. When WTI fell to $58 last December, both stocks took it on the chin. A 30% simultaneous drawdown in the two would carve directly into roughly 8% of the fund before the rest of the book has a vote. We may be close to an Iran deal that could take energy stocks lower again.

• The dividend cuts the filter did not prevent. Many of the stocks here are not immune to dividend cuts, and this is why SCHD took so long to make a comeback. It went on a 4-year stretch where it barely returned anything and investors started fleeing elsewhere. But again, SCHD is back to being highly relevant post-recovery.

How SCHD compares to the simpler alternative

The Vanguard High Dividend Yield ETF (NYSEARCA:VYM) charges 0.04%, owns roughly 550 stocks, and runs a far flatter weighting. You give up SCHD’s quality screen, and historically you give up some total return. In exchange, VYM’s top ten rarely crosses 25% of assets. For the retiree who picked SCHD because they wanted diversification, VYM is the version that actually delivers it.

You should also take into account the fact that VYM has outperformed SCHD and is up 72.3%. You could think of it as a middleground between SCHD and the SPY. However, I would warn that your dividend yield here is a percent lower, with negative revenue growth. Not only that, the SPY is up 20.7% so far this year, whereas VYM is up 11.23% this year. Over 10 years, SCHD is up 245% against VYM’s 212%, so there’s a good chance VYM’s outperformance in the past 5 years was a fluke.

So, should you buy SCHD?

SCHD remains one of the cleanest dividend products on the shelf: cheap, qualified-dividend-friendly, and built around businesses that have actually paid for a decade. It belongs in the income sleeve of an investor who understands they are buying ten meaningful single-stock bets wearing the costume of an index fund.

If you cannot stomach pharma patent cliffs and energy cycles dictating a chunk of your distributions, consider pairing SCHD with a flatter-weighted dividend ETF rather than leaning on it as a standalone diversifier.